RS58809B1 - Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta - Google Patents

Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta

Info

Publication number
RS58809B1
RS58809B1 RS20190710A RSP20190710A RS58809B1 RS 58809 B1 RS58809 B1 RS 58809B1 RS 20190710 A RS20190710 A RS 20190710A RS P20190710 A RSP20190710 A RS P20190710A RS 58809 B1 RS58809 B1 RS 58809B1
Authority
RS
Serbia
Prior art keywords
bladder
prevention
treatment
urinary tract
tract diseases
Prior art date
Application number
RS20190710A
Other languages
English (en)
Inventor
Taisuke Takahashi
Takanori Koike
Kenji Negoro
Hiroaki Tanaka
Jun Maeda
Kazuhiro Yokoyama
Hajime Takamatsu
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of RS58809B1 publication Critical patent/RS58809B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
RS20190710A 2014-06-06 2015-06-05 Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta RS58809B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014118046 2014-06-06
PCT/JP2015/066321 WO2015186821A1 (ja) 2014-06-06 2015-06-05 2-アシルアミノチアゾール誘導体またはその塩
EP15803484.3A EP3153511B1 (en) 2014-06-06 2015-06-05 2-acylaminothiazole derivative for use in the prevention or treatment of bladder/urinary tract diseases

Publications (1)

Publication Number Publication Date
RS58809B1 true RS58809B1 (sr) 2019-07-31

Family

ID=54766887

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190710A RS58809B1 (sr) 2014-06-06 2015-06-05 Derivat 2-acilaminotiazola za upotrebu u prevenciji ili lečenju oboljenja bešike/urinarnog trakta

Country Status (34)

Country Link
US (2) USRE49111E1 (sr)
EP (1) EP3153511B1 (sr)
JP (1) JP6319436B2 (sr)
KR (1) KR102482844B1 (sr)
CN (2) CN106414438B (sr)
AR (1) AR100748A1 (sr)
AU (1) AU2015269449B2 (sr)
BR (1) BR112016028270B1 (sr)
CA (1) CA2950564C (sr)
CO (1) CO2017000044A2 (sr)
CY (1) CY1122290T1 (sr)
DK (1) DK3153511T3 (sr)
EA (1) EA031866B1 (sr)
ES (1) ES2732066T3 (sr)
HR (1) HRP20190943T1 (sr)
HU (1) HUE043496T2 (sr)
IL (1) IL249356B (sr)
LT (1) LT3153511T (sr)
MA (1) MA39950B1 (sr)
ME (1) ME03438B (sr)
MX (1) MX370140B (sr)
MY (1) MY197712A (sr)
NZ (1) NZ727142A (sr)
PH (1) PH12016502405A1 (sr)
PL (1) PL3153511T3 (sr)
PT (1) PT3153511T (sr)
RS (1) RS58809B1 (sr)
SA (1) SA516380427B1 (sr)
SG (2) SG10202000463YA (sr)
SI (1) SI3153511T1 (sr)
TR (1) TR201908676T4 (sr)
TW (2) TWI689507B (sr)
UA (1) UA122208C2 (sr)
WO (1) WO2015186821A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2103110B1 (en) 2006-12-20 2014-03-26 GVBB Holdings S.A.R.L Embedded audio routing switcher
CA2959290A1 (en) 2014-08-26 2016-03-03 Astellas Pharma Inc. 2-aminothiazole derivative or salt thereof
WO2018116139A1 (en) 2016-12-19 2018-06-28 Novartis Ag New picolinic acid derivatives and their use as intermediates
JPWO2019189766A1 (ja) * 2018-03-30 2021-04-08 持田製薬株式会社 新規ビアリールアミド誘導体
CN111718293A (zh) * 2019-03-18 2020-09-29 持田制药株式会社 双芳基酰胺衍生物的制造方法
EP3967311A1 (en) 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
WO2024122076A1 (ja) * 2022-12-09 2024-06-13 株式会社旭飛薬業 体液調節剤、体液調節用組み合わせ剤及び化合物の使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP2001278872A (ja) * 2000-03-27 2001-10-10 Banyu Pharmaceut Co Ltd 新規アミノチアゾール誘導体
WO2001090081A1 (en) * 2000-05-25 2001-11-29 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
WO2003037862A1 (fr) 2001-10-30 2003-05-08 Nippon Shinyaku Co., Ltd. Derives amide, et medicaments correspondants
ES2416304T3 (es) 2002-01-18 2013-07-31 Astellas Pharma Inc. Derivado de 2-acilaminotiazol o sal del mismo
TWI242478B (en) 2002-08-01 2005-11-01 Masami Nakamoto Metal nanoparticle and process for producing the same
TW200410951A (en) * 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
EP1647553A4 (en) 2003-07-17 2008-12-31 Astellas Pharma Inc 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF
JP4665769B2 (ja) 2005-01-12 2011-04-06 アステラス製薬株式会社 アシルアミノチアゾール誘導体の製造法
JP4774995B2 (ja) 2005-01-12 2011-09-21 アステラス製薬株式会社 アシルアミノチアゾール誘導体を有効成分とする医薬組成物
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
EP2206707B1 (en) 2007-10-24 2014-07-23 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
KR101764952B1 (ko) * 2010-07-29 2017-08-03 리겔 파마슈티칼스, 인크. Ampk-활성화 헤테로시클릭 화합물 및 그의 사용 방법
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 2-醯胺噻唑衍生物或其鹽

Also Published As

Publication number Publication date
CN106414438B (zh) 2019-12-31
BR112016028270A2 (pt) 2022-07-19
IL249356B (en) 2019-11-28
BR112016028270B1 (pt) 2023-05-02
SI3153511T1 (sl) 2019-08-30
CA2950564A1 (en) 2015-12-10
MA39950A (fr) 2017-04-12
USRE49111E1 (en) 2022-06-21
SG11201610201UA (en) 2017-01-27
JPWO2015186821A1 (ja) 2017-04-20
ME03438B (me) 2020-01-20
KR20170013987A (ko) 2017-02-07
US20170197955A1 (en) 2017-07-13
WO2015186821A1 (ja) 2015-12-10
IL249356A0 (en) 2017-02-28
NZ727142A (en) 2022-10-28
CO2017000044A2 (es) 2017-03-31
MY197712A (en) 2023-07-09
UA122208C2 (uk) 2020-10-12
MX370140B (es) 2019-12-03
TWI745877B (zh) 2021-11-11
CY1122290T1 (el) 2021-01-27
CN110845490A (zh) 2020-02-28
CN106414438A (zh) 2017-02-15
HRP20190943T1 (hr) 2019-09-20
DK3153511T3 (da) 2019-06-24
HUE043496T2 (hu) 2019-08-28
PH12016502405B1 (en) 2017-02-20
TWI689507B (zh) 2020-04-01
AR100748A1 (es) 2016-10-26
MA39950B1 (fr) 2019-08-30
AU2015269449B2 (en) 2019-03-14
TR201908676T4 (tr) 2019-07-22
BR112016028270A8 (pt) 2023-01-17
CN110845490B (zh) 2023-03-28
SA516380427B1 (ar) 2019-11-28
PH12016502405A1 (en) 2017-02-20
EA201692469A1 (ru) 2017-05-31
EP3153511A4 (en) 2017-12-06
PT3153511T (pt) 2019-06-28
EP3153511B1 (en) 2019-05-15
ES2732066T3 (es) 2019-11-20
EA031866B1 (ru) 2019-03-29
EP3153511A1 (en) 2017-04-12
LT3153511T (lt) 2019-07-10
JP6319436B2 (ja) 2018-05-09
US9951060B2 (en) 2018-04-24
PL3153511T3 (pl) 2019-09-30
MX2016016134A (es) 2017-03-08
TW201613914A (en) 2016-04-16
KR102482844B1 (ko) 2022-12-30
CA2950564C (en) 2023-03-07
SG10202000463YA (en) 2020-02-27
AU2015269449A1 (en) 2016-12-22
TW202026294A (zh) 2020-07-16

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
HRP20180876T1 (hr) Adc duokarmicina, namijenjeni upotrebi u liječenju raka mokraćnog mjehura
LT3194000T (lt) Lenktas šlapimo kateteris
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
ME03438B (me) DERIVAT 2-ACILAMINOTIAZOLA ZA UPOTREBU U PREVENCIJI ILI LEčENJU OBOLJENJA BESIKE / URINARNOG TRAKTA
IL249458A0 (en) ppar compounds for use in the treatment of fibrotic diseases
IL250596A0 (en) The composition for the treatment and prevention of urinary tract infections
IL247969B (en) A medicinal component for use in the treatment of infections
PT3192512T (pt) Nova composição farmacêutica para prevenção e/ou tratamento de incontinência urinária
GB201420030D0 (en) Urinary catheter
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
GB201412972D0 (en) Flushable urinary catheter
SG10201405850PA (en) Composition for prevention or treatment of urinary tract infection
EP3242667C0 (en) FINAFLOXACIN FOR USE IN THE TREATMENT OF URINARY TRACT INFECTIONS
GB201614869D0 (en) Treatment of urinary tract disorders
AU2014902125A0 (en) A device for diagnosis and treatment of the urinary system